雖然這篇figaro-dkd鄉民發文沒有被收入到精華區:在figaro-dkd這個話題中,我們另外找到其它相關的精選爆讚文章
[爆卦]figaro-dkd是什麼?優點缺點精華區懶人包
你可能也想看看
搜尋相關網站
-
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#1Cardiovascular Events with Finerenone in Kidney Disease ...
由 B Pitt 著作 · 2021 · 被引用 64 次 — In the FIGARO-DKD trial, finerenone therapy improved cardiovascular outcomes, as compared with placebo, in patients with type 2 diabetes who had ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#2Efficacy and Safety of Finerenone in Subjects With Type 2 ...
Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses From the FIGARO-DKD Trial. Circulation.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#3Finerenone in Reducing Cardiovascular Mortality and ...
The FIGARO-DKD trial showed that finerenone has salutary effects on CV outcomes among patients with T2DM and CKD, who were on a background ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#4Design and Baseline Characteristics of the ... - PubMed
由 LM Ruilope 著作 · 2019 · 被引用 95 次 — FIGARO-DKD is a randomized, double-blind, placebo-controlled, parallel-group, event-driven trial running in 47 countries with an expected duration of ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#5Finerenone Reduces Risk of Incident Heart Failure in Patients ...
The FIGARO-DKD trial included patients at high cardiovascular risk, with a broader spectrum of patients with CKD, yet overall, less advanced ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#6Bayer's finerenone meets primary endpoint in ... - News - Bayer
FIGARO -DKD is a randomized, double-blind, placebo-controlled, parallel-group, event-driven Phase III study investigating finerenone versus ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#7Results From FIGARO-DKD: Finerenone's Impact on Type 2 ...
2021年9月17日 — Rajiv Agarwal, MD, MS: The primary end point in the FIGARO-DKD study was the 4-point MACE [major adverse cardiac event], which is described as ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#8Finerenone Reduces CV Outcomes in Patients With Early ...
2021年8月28日 — In FIGARO-DKD, which was published simultaneously in the New England Journal of Medicine, 62% of patients had a normal estimated glomerular ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#9FIGARO-DKD adds new evidence to the ... - Oxford Academic
FIGARO -DKD (Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease), an industry-promoted, phase 3, ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#10Finerenone shows HF benefit in mild to moderate diabetic ...
FIGARO -DKD was a double-blind trial that involved 7,437 adults with type 2 diabetes and stage 1-4 CKD who were randomly assigned oral finerenone ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#11ESC: Finerenone Demonstrates CVD Benefit in FIGARO-DKD
Finerenone bested placebo in the FIGARO-DKD trial, giving this patient population another potential treatment […]
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#12FIGARO-DKD | Joslin Diabetes Center
The purpose of this study is to demonstrate whether finerenone is superior to placebo in delaying the time to first occurrence of cardiovascular mortality in ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#13Finerenone cardioprotective across broad range of renal risk
ESC 2021 news: FIGARO-DKD: Finerenone protects against adverse cardiovascular outcomes in people with type 2 diabetes and mild or moderate ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#14Bayer Announces KERENDIA® (finerenone) Reduces the ...
FIGARO -DKD is the first contemporary Phase III cardiorenal trial with the majority of patients with stages 1-2 CKD (estimated glomerular ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#15FIDELIO-DKD and FIGARO-DKD endpoints. a Kidney failure ...
FIDELIO-DKD and FIGARO-DKD endpoints. a Kidney failure defined as occurrence of ESKD (initiation of chronic dialysis for 90 days or renal transplantation) ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#16FIGARO-DKD Demonstrates Finerenone's Potential in Mild ...
FIGARO -DKD concluded use of finerenone was associated with a 13% reduction in the primary outcome, which investigators purport demonstrates ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#17Bayer Reports Results of Finerenone in P- III FIGARO-DKD CV
The P-III FIGARO-DKD study involves assessing the efficacy and safety of finerenone (10/20mg- PO- qd) + SoC vs PBO + SoC in ~7400 patients with CKD and T2D ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#18Finerenone improves outcomes in patients with mild-to ...
FIGARO -DKD trial presented in a Hot Line Session today at ESC Congress 2021 ... Sophia Antipolis, France – 28 Aug 2021: Finerenone reduces the ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#19FIGARO-DKD - Clinical Trial Results
FIGARO -DKD ... Taking too long? Reload document. | Open in new tab · Download [6.29 MB]. Disclosures: TBD.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#20Pop Quiz: FIGARO-DKD Trial Outcomes | Consultant360
In FIGARO-DKD, the primary outcome measure is a composite of death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#21Bertram Pitt, MD: Interpreting Data from FIDELIO-DKD and ...
Bertram Pitt, MD, offers perspective on how he interprets data from both FIDELIO-DKD and FIGARO-DKD inform the use of finerenone in patients ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#22Finerenone Improves CV Outcomes in Patients with T2D, CKD ...
As a result, the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease (FIGARO-DKD) trial evaluated if ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#23European Society of Cardiology 在Twitter 上:"#FIGARO-DKD ...
#FIGARO-DKD trial: finerenone reduces the risk of #cardiovascular morbidity and mortality in patients with mild-to-moderate kidney disease ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#24The FIGARO-DKD Trial | Hurst's the Heart Updates
Pumill C, Al-Kazaz M. Pumill C, & Al-Kazaz M Pumill, Chris, and Mohamed Al-Kazaz. (2021). The figaro-dkd trial. Fuster V. Fuster V Fuster, Valentin.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#25Bayer's Finerenone Meets Primary Endpoint in ... - BioSpace
FIGARO -DKD is a randomized, double-blind, placebo-controlled, parallel-group, event-driven Phase III study that investigated finerenone versus ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#26FIGARO-DKD Data Summary Slide
FIGARO -DKD. Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. Purpose: To evaluate whether oral finerenone, in addition to.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#27FIGARO-DKD 为Finerenone 对2 型糖尿病和慢性肾病患者的心 ...
Comment on 'Cardiovascular events with finerenone in kidney disease and type 2 diabetes' published in the New England Journal of Medicine ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#28Diabetes Distilled: FIDELIO, FIGARO, MAGNIFICO!
Alongside the FIDELIO-DKD trial, FIGARO-DKD confirms clear renal and cardiovascular benefits for finerenone across a broad range of eGFR and ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#29Bayer's Finerenone Meets Primary Endpoint in Phase III ...
Whippany, N.J., May 10, 2021 – Bayer's Phase III cardiovascular outcomes study FIGARO-DKD, evaluating the efficacy and safety of the investigational drug ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#30FIDELIO-DKD & FIGARO-DKD – For Patients with Type 2 ...
The FIDELIO-DKD and FIGARO-DKD studies are clinical research studies for adults with type 2 diabetes and diabetic kidney disease (DKD).
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#31Finerenone Delays Progression in CKD With Diabetes
The goal of the FIGARO-DKD study is to investigate the safety and efficacy of finerenone versus placebo plus standard of care in terms of ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#32Design and Baseline Characteristics of ... - Karger Publishers
FIGARO -DKD is an international, multicenter, randomized, double-blind, placebo-controlled, parallel-group, event-driven study formally ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#33Kidney Week - American Society of Nephrology
Finerenone and Kidney Outcomes in Patients with CKD and Type 2 Diabetes: Results from FIGARO-DKD. Session Information.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#34Finerenone in Predominantly Advanced CKD and Type 2 ...
FIDELIO-DKD (FInerenone in reducing kiDnEy faiLure and dIsease prOgression in ... It is important to note that the proportion of patients in FIGARO-DKD who ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#35Medline ® Abstract for Reference 136 of 'Inflammation in ...
... Kolkhof P, Nowack C, Joseph A, FIDELIO-DKD and FIGARO-DKD Investigators ... Disease) and FIGARO-DKD (FInerenone in reducinG cArdiovascular moRtality and ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#36FIGARO-DKD: Finerenone CV benefit extends to wide ...
The large, phase III FIGARO-DKD trial strengthen the evidence on cardiovascular benefit (CV) of the nonsteroidal mineralocorticoid receptor ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#37Setting the route for CKD and type 2 diabetes care - EASD
Setting the route for CKD and type 2 diabetes care: clinical consequences of the FIDELIO-DKD and FIGARO-DKD data. Session: Finerenone: a new approach to ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#38Bayer's Finerenone Meets Primary Endpoint in Phase III ...
Bayer's Finerenone Meets Primary Endpoint in Phase III FIGARO-DKD Cardiovascular Outcomes Study in Patients With Chronic Kidney Disease and ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#39Finerenone Reduces Risk of Incident HF in Patients with T2D ...
... mineralocorticoid receptor antagonist, significantly reduced new-onset HF and improved other HF outcomes in the FIGARO-DKD trial.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#40Amplification of the presentation of the main results of the ...
The FIGARO-DKD study was presented during the Hot Line session on August 28 at ESC Congress 2021, and simultaneously published in the New ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#41Expanding the therapy options for diabetic kidney disease
FIGARO -DKD was a cardiovascular out- come trial6 that also involved patients with. T2D and CKD on treatment with ACE inhi- bitors or ARBs, but its inclusion ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#42finerenone in type 2 diabetes and chronic kidney disease (CKD)
FIGARO -DKD investigated the effects of finerenone on CV and renal outcomes in patients with mild-to-moderate kidney disease and T2DM.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#43FIGARO-DKD Trial - Slideshare
Meritxell Soler Costa FIGARO-DKD Effect of Finerenona on cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes: Results of the ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#44European Society of Cardiology - #FIGARO-DKD trial
FIGARO -DKD trial: finerenone reduces the risk of #cardiovascular morbidity and mortality in patients with mild-to-moderate kidney disease and type 2...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#45FIGARO-DKD adds new evidence to the cardiovascular ...
FIGARO -DKD adds new evidence to the cardiovascular benefits of finerenone across the spectrum of patients with type 2 diabetes and chronic ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#46Retour sur l'essai FIGARO-DKD - La finérénone diminue les ...
Retour sur l'essai FIGARO-DKD - La finérénone diminue les événements cardiovasculaires chez les patients diabétiques de type 2 ayant une maladie rénale ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#47Nonsteroidal MRA reduces risk of CV outcomes in patients ...
FIGARO -DKD: finerenone in patients with chronic kidney disease and type 2 diabetes. Presented at the ESC congress 2021 by: Prof.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#48Finerenone and kidney outcomes in patients with CKD and ...
Finerenone and kidney outcomes in patients with CKD and type 2 diabetes: results from figaro-DKD. Bakris GL, Ruilope LM, Rossing P, Anker SD, Pitt B, ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#49FIGARO-DKD: ¿Una nueva opción para reducir el riesgo ...
Una droga con menor potencial de causar hipercalemia es bien interesante en el escenario de pacientes con ERC. Metodología Simplificada del FIGARO-DKD. • Ensayo ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#50Does Finerenone Reduce Risk for Heart Failure Events in ...
... reduces risk of incident heart failure in patients with chronic kidney disease and type 2 diabetes: Analyses from the FIGARO-DKD trial.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#51Bayer's phase III study FIGARO-DKD of finerenone in patients ...
FIGARO -DKD is a randomized, double-blind, placebo-controlled, parallel-group, event-driven phase III study investigating finerenone versus ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#52ICTRP Search Portal - WHO | World Health Organization
... eye examinations of patients participating in studies FIDELIO-DKD and FIGARO-DKD to explore whether Finerenone can delay the progression ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#53ReachMD CME: FIGARO-DKD and FIDELITY Analysis - Apple ...
CME credits: 0.25 Valid until: 31-08-2022 Claim your CME credit at https://reachmd.com/programs/cme/figaro-dkd-and-fidelity-analysis-key-takeaways/12827/ ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#54|NIPH Clinical Trials Search - 国立保健医療科学院
A Non-blinded Retrospective Biomarker add-on Study to FIGARO-DKD for Bioprofiling the Pharmacodynamic Response to Finerenone in FIGARO-DKD ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#55Finerenone Improves Cardiovascular Outcomes in Patients ...
The phase 3 FIGARO-DKD study evaluating finerenone, a nonsteroidal selective mineralocorticoid receptor antagonist, for the reduction of ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#56Long-term cardiorenal efficacy of finerenone in patients with ...
Both FIGARO-DKD (2) and FIDELIO-DKD (3) focused on comparing the cardiorenal outcomes of finerenone with those of placebo in patients with T2D and CKD.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#57| Australian Clinical Trials
An add-on Study to the FIGARO-DKD Study Called FIGARO-BM to Learn About the Link Between Biomarkers (Substances in the Blood Used as Indicators of ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#58FIGARO-DKD-_-FIDELITY.pdf - Sociedad Interamericana de ...
Análisis de FIGARO-DKD / FIDELITY. Eventos cardiovasculares con finerenona en pacientes con insuficiencia renal y diabetes.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#59Finerenone譜寫CKD合併T2D治療新篇章 - 每日頭條
FIGARO -DKD研究是一項國際、隨機、雙盲、安慰劑對照、多中心III期臨床研究,納入包括中國在內的47個國家、共計7437例輕中度CKD合併T2D患者,所有患者 ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#602021年歐洲糖尿病學會年會(EASD)學術新知上架囉
編號19 · Finerenone提供第2型糖尿病患者腎臟保護的新方法-為CKD和第2型糖尿病照護設定路線:FIDELIO-DKD 和FIGARO-DKD 數據的臨床結果.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#61Estudio FIGARO-DKD - MedEcs
ESCCongress - El estudio FIGARO-DKD demostró un efecto beneficioso de la finerenona en diabéticos con enfermedad renal avanzada.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#62CME; Finerenone, eGFR, hyperkalemia, SGLT-2, heart failure,
FIGARO -DKD and FIDELITY Analysis: Key Takeaways. 0.25 credits. 15 minutes. 9. LikeLiked. Share. Save. ReachMD Healthcare Image. Restart.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#63ESC 2021: FIDELITY Confirms Benefits of Finerenone ...
For FIDELIO-DKD and FIGARO-DKD, patients with type 2 diabetes mellitus and chronic kidney disease were randomized to 10 to 20 mg of finerenone ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#64Protect Your Kidneys and Your Heart | diaTribe
The FIGARO-DKD study examined the frequency of heart-related outcomes such as death, non-fatal heart attack, non-fatal stroke, and ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#65The Role of Finerenone in the Management of Diabetic ...
Diabetic kidney disease (DKD) constitutes the lion's share of patients with ... The results of the ongoing FIGARO-DKD trial will provide ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#66FIGARO-DKD Archives - Medical Conferences
Bertram Pitt, University of Michigan School of Medicine, USA; Trial: Phase 3, FIGARO-DKD; Conference: ESC 2021. 26 October, 2021 12:40 ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#67Hyperkalemia with Mineralocorticoid Receptor Antagonist Use ...
Both FIDELIO-DKD and FIGARO-DKD enrolled mainly diabetic and albuminuric patients with CKD (diabetic nephropathy), but we do not yet have evidence for ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#68Finerenone Reduces CV Issues in T2D Patients With ...
Now, in the recent Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease (FIGARO-DKD) trial, ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#69Bayer data for kidney disease hope finerenone sets up filings -
Bayer's blockbuster ambitions for diabetic kidney disease (DKD) drug candidate ... A second ongoing phase 3 trial – called FIGARO-DKD – is ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#70FIGARO-DKD研究結果ESC年會重磅發佈 - 壹讀
FIGARO -DKD研究為Finerenone在T2DM合併CKD患者中開展的又一項全球、多中心、大型Ⅲ期臨床研究,以心血管複合終點為主要研究結局。
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#71Design and Baseline Characteristics of the Finerenone in ...
In this paper, we describe the design of Finerenone in Reduc- ing CV Mortality and Morbidity in Diabetic Kidney. Disease (FIGARO-DKD; ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#72Design and Baseline Characteristics of the ... - Europe PMC
The Finerenone in Reducing CV Mortality and Morbidity in Diabetic Kidney Disease (FIGARO-DKD) trial aims to assess the efficacy and safety of finerenone ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#73CKDのT2D患者へのfinerenoneの有益性を示す:FIGARO-DKD
【背景】 Finerenoneは、新規非ステロイド選択的ミネラルコルチコイド受容体拮抗薬(MRA)である。University of MichiganのPittら(FIGARO-DKD)は、RAAS阻害薬で治療 ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#74Finerenone benefits patients with diabetes ac | EurekAlert!
The results of FIGARO-DKD, reported at ESC Congress 2021, showed that finerenone reduced the risk of cardiovascular events in patients with mild ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#75Clinical Trials - Nephrology - UT Health San Antonio
Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease (FIGARO-DKD).
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#76Reduced CV outcomes with nonsteroidal MRA in patients with ...
FIGARO -DKD: finerenone in patients with chronic kidney disease and type 2 diabetes. Presented at the ESC congress 2021 by: Prof.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#77ESC: Finerenone Improves Outcomes in Patients with Mild-to ...
FIGARO -DKD trial presented in a Hot Line Session today at ESC Congress 2021 News.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#78Supplementary Material for: Design and Baseline ... - Figshare
Patients and Methods: The Finerenone in Reducing CV Mortality and Morbidity in Diabetic Kidney Disease (FIGARO-DKD) trial aims to assess the efficacy and ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#79ESC 2021: Late-breaking Science Video Collection
ESC 2021 Discussion: The FIGARO-DKD Trial. Bertram Pitt, Harriette Van Spall. ESC 2021 Discussion: The EMPEROR-Preserved Trial · ESC 2021 ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#80EudraCT - EU Clinical Trials Register
Subjects with a clinical diagnosis of DKD based on either of the following criteria at the Run-in and Screening Visit:
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#81Bayer's finerenone meets primary ... - PipelineReview.com
Bayer's finerenone meets primary endpoint in Phase III FIGARO-DKD cardiovascular outcomes study in patients with chronic kidney disease and ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#82Mineralocorticoid Receptor Antagonists in Diabetic Kidney ...
In FIGARO-DKD, a total of 7,437 patients were allocated to placebo or finerenone group and followed-up for 3.4 years, a primary outcome event ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#83Finerenone scores second pivotal-trial success in patients ...
Top-line results from FIGARO-DKD, the second pivotal trial for finerenone in patients with type 2 diabetes and diabetic kidney disease, ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#84Diabetic Kidney Disease (DKD), CMHC Digital Education Hub
CME / CE Virtual Symposium, Webcasts; DKD News Digest ... Results from FIGARO-DKD trial ... Finerenone reduces risk of new-onset AF in DKD.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#85Finerenone in Diabetic Nephropathy - NephJC
The FIDELIO-DKD trial represents another attempt at this treatment, ... Thus 1374 patients were switched from FIGARO to FIDELIO-DKD (here).
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#86Bayer's cardiovascular drug shows impressive Phase III results
The randomised FIGARO-DKD Phase III study investigated finerenone versus placebo in around 7,400 patients with CKD and T2D worldwide, ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#87Finerenone Cuts Kidney, Heart Risks in CKD and T2D
FIDELIO-DKD, together with its ongoing sister study, FIGARO-DKD, form the largest clinical trial program in patients with CKD and type 2 ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#88Drug Study Offers New Hope to Patients with Both Chronic ...
A sister study of FIDELIO-DKD called FIGARO-DKD is being performed in even an earlier stage of kidney disease.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#89Journal Pre-proof - Kidney International Reports
DKD trial in patients with CKD associated with type 2 diabetes, ... FIGARO-DKD used the SGLT2-inhibitors in combination with finerenone.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#90Cardiovascular events with finerenone in kidney disease and ...
The FIGARO-DKD study (NCT02545049) was a Phase III, multicentre, randomised clinical trial. The trial comprised run-in, screening, and double-blind treatment ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#91la Finérénone améliore le pronostic cardiovasculaire et rénal ...
D'après la présentation de Bertram Pitt (Ann Arbor, États-Unis) : "FIGARO-DKD: finerenone in patients with chronic kidney disease and type 2 ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#92Reduced Risk for CV, Kidney Failure Outcomes With ...
Patients with CKD and T2D were randomly assigned 1:1 to treatment with finerenone or placebo, and the results of the FIDELIO-DKD and the FIGARO- ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#93FIDELIO-DKD - Wiki Journal Club
The Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease (FIGARO-DKD) trial, a study specifically ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#94Cardiac Events With Type 2 Diabetes, Kidney Disease ...
The Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease (FIGARO-DKD) trial was conducted by Bayer, ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?>
figaro-dkd 在 コバにゃんチャンネル Youtube 的最讚貼文
figaro-dkd 在 大象中醫 Youtube 的最佳貼文
figaro-dkd 在 大象中醫 Youtube 的最讚貼文